Dr. Palanca-Wessels is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
916 23rd Ave East
Seattle, WA 98112
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2008- University of WashingtonFellowship, Hematology and Medical Oncology, 2003 - 2006
- University of WashingtonResidency, Internal Medicine, 2001 - 2003
- University of Washington School of MedicineClass of 2001
Certifications & Licensure
WA State Medical License 2003 - 2026- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 4 citationsSystematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.Harshabad Singh, Ashley Kang, Lisa Bloudek, Ling-I Hsu, Maria Corinna Palanca-Wessels
JNCI Cancer Spectrum. 2024-01-04 - 1 citationsReal-World Treatment Patterns in Patients With HER2-Amplified Metastatic Colorectal Cancer: A Clinical-Genomic Database Study.John H Strickler, Ling-I Hsu, Phoebe Wright, Michael Stecher, Muriel F Siadak
Journal of the National Comprehensive Cancer Network. 2023-08-01 - 19 citationsTherapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Maureen Ryan, Maria Corinna Palanca-Wessels, Brian Schimpf, Kristine A. Gordon, Heather Kostner
Blood. 2017-11-02
Press Mentions
ALCANZA Study: Brentuximab Vedotin Superior in CD30-Expressing Cutaneous T Cell LymphomaDecember 3rd, 2016
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
